Title :

Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.

Author(s) :

Lee, Catherine J [Auteur]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Beelen, Dietrich [Auteur]
Finke, Jurgen [Auteur]
Blaise, Didier [Auteur]
Ganser, Arnold [Auteur]
Itala-Remes, Maija [Auteur]
Chevallier, Patrice [Auteur]
Labussiere-Wallet, Helene [Auteur]
Maertens, Johan [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bourhis, Jean-Henri [Auteur]
Mailhol, Audrey [Auteur]
Mohty, Mohamad [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Savani, Bipin N [Auteur]
Nagler, Arnon [Auteur]

Journal title :

American Journal of Hematology

Abbreviated title :

Am. J. Hematol.

Volume number :

94

Pages :

431-438

Publication date :

2019-04

ISSN :

1096-8652

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Therapy-related acute myeloid leukemia (t-AML) arises as a late complication following antecedent solid tumors or hematologic diseases and their associated treatments. There are limited data regarding risk factors and ...
Show more >Therapy-related acute myeloid leukemia (t-AML) arises as a late complication following antecedent solid tumors or hematologic diseases and their associated treatments. There are limited data regarding risk factors and outcomes following allogeneic hematopoietic cell transplantation (HCT) for t-AML following a prior solid tumor, and furthermore, the impact of myeloablative (MAC) vs reduced-intensity conditioning (RIC) on survival is unknown. The acute leukemia working party (ALWP) of the European society for blood and bone marrow transplantation (EBMT) performed a large registry study that included 535 patients with t-AML and prior solid tumor who underwent first MAC or RIC allogeneic HCT from 2000-2016. The primary endpoints of the study were OS and LFS. Patients receiving RIC regimens had an increase in relapse incidence (hazard ratio [HR], 1.52; 95% confidence interval [CI] 1.02-2.26; P = 0.04), lower LFS (HR, 1.52; 95% CI 1.12-2.05, P = 0.007), and OS (HR, 1.51; CI 1.09-2.09; P = 0.012). There were no differences in NRM and GRFS. Importantly, LFS and OS were superior in patients receiving ablative regimens due to a decrease in relapse. As NRM continues to decline in the current era, it is conceivable that outcomes of HCT for t-AML with prior solid tumor may be improved by careful patient selection for myeloablative regimens.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2019-10-22T08:09:18Z
2024-01-23T12:34:40Z